Daniel MBA - Acumen Pharmaceuticals President CEO
| ABOS Stock | USD 2.37 0.06 2.60% |
CEO
Daniel MBA is President CEO of Acumen Pharmaceuticals
| Age | 54 |
| Address | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Phone | 434 297 1000 |
| Web | https://acumenpharm.com |
Acumen Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2099) % which means that it has lost $0.2099 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3283) %, meaning that it created substantial loss on money invested by shareholders. Acumen Pharmaceuticals' management efficiency ratios could be used to measure how well Acumen Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.22 in 2024. At this time, Acumen Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 66.7 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Found 5 records | CEO Age | ||
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Malte MD | Hookipa Pharma | 62 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 |
Acumen Pharmaceuticals Leadership Team
Elected by the shareholders, the Acumen Pharmaceuticals' board of directors comprises two types of representatives: Acumen Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acumen. The board's role is to monitor Acumen Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acumen Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acumen Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Bockenstette, Ex HR | ||
| JD Esq, Chief Secretary | ||
| Siew MS, Assistant Operations | ||
| Grant Krafft, CoFounder | ||
| Robyn MA, Manager Communications | ||
| Daniel MBA, President CEO | ||
| James Doherty, President Officer | ||
| Caleb Finch, CoFounder | ||
| Kelly Carranza, Finance President | ||
| Janice Hitchcock, VP Affairs | ||
| William Klein, CoFounder | ||
| Russell MS, Chief Officer | ||
| Matt Zuga, CFO Officer | ||
| Eric MD, Chief Officer | ||
| Liean MS, VP CMC | ||
| Alex MBA, VP Relations |
Acumen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acumen Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (29.49 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 11.23 % | ||||
| Shares Owned By Institutions | 78.48 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.